Wednesday, July 8, 2026

Patent intelligence · US

US 11723959

Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide

granted A61KA61K2039/505A61K38/00A61K38/47
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 70
Patent details — US 11723959
Jurisdiction
US
Status
granted
Grant date
Aug 15, 2023
Expiration
Aug 10, 2043
Applicant
HALOZYME, INC.
Claims
13
CPC classes
A61K, A61K2039/505, A61K38/00, A61K38/47
View on Google Patents ↗

Quick answer

US 11723959 (Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide) is held by HALOZYME, INC.. Status: granted. Granted Aug 15, 2023. Expires Aug 10, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
HALOZYME, INC.
Grant date
Expiration
Claims
13
CPC classes
A61K, A61K2039/505, A61K38/00, A61K38/47, A61K39/395, A61K9/0048

More from HALOZYME, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12421308

    Anti-G-CSF antibodies and uses thereof

    ME Therapeutics Inc. · Expires Sep 18, 2045

    granted
  2. US 12371685

    PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof

    HALOZYME, INC. · Expires Jul 24, 2045

    granted
  3. US 12264345

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Expires Mar 27, 2045

    granted
  4. US 12195773

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Expires Jan 9, 2045

    granted
  5. US 12178860

    Hyaluronidase enzyme formulations for high volume administration

    HALOZYME, INC. · Expires Dec 26, 2044

    granted
  6. US 12152262

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Expires Nov 21, 2044

    granted
  7. US 12123035

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Expires Oct 17, 2044

    granted
  8. US 12110520

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Expires Oct 3, 2044

    granted

Frequently asked questions

What is US patent 11723959?

US 11723959 (Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide) is held by HALOZYME, INC.. Status: granted. Granted Aug 15, 2023. Expires Aug 10, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11723959?

HALOZYME, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 70 pharmaceutical patents for this assignee.

When does US 11723959 expire?

Our index shows an expiration date of Aug 10, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.